Barclays PLC Catalyst Pharmaceuticals, Inc. Transaction History

Barclays PLC

  • $377 Billion
  • Q3 2024

A detailed history of Barclays PLC transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Barclays PLC holds 248,458 shares of CPRX stock, worth $5.28 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
248,458
Previous 248,458 -0.0%
Holding current value
$5.28 Million
Previous $4.94 Million -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 15, 2024
BUY
$15.19 - $21.35 $2.13 Million - $2.99 Million
140,129 Added 129.36%
248,458 $4.94 Million
Q2 2024

Aug 14, 2024
SELL
$14.68 - $16.92 $476,688 - $549,426
-32,472 Reduced 23.06%
108,329 $1.68 Million
Q1 2024

May 15, 2024
SELL
$13.18 - $17.11 $2.14 Million - $2.78 Million
-162,284 Reduced 53.54%
140,801 $2.24 Million
Q4 2023

Feb 15, 2024
SELL
$11.78 - $17.29 $327,731 - $481,025
-27,821 Reduced 8.41%
303,085 $5.1 Million
Q3 2023

Nov 07, 2023
SELL
$11.69 - $15.02 $3.88 Million - $4.98 Million
-331,779 Reduced 50.07%
330,906 $3.87 Million
Q2 2023

Aug 03, 2023
BUY
$11.5 - $18.08 $5.39 Million - $8.48 Million
468,846 Added 241.87%
662,685 $8.91 Million
Q1 2023

May 04, 2023
SELL
$14.34 - $21.05 $1.4 Million - $2.05 Million
-97,614 Reduced 33.49%
193,839 $3.21 Million
Q4 2022

Feb 13, 2023
BUY
$12.25 - $19.5 $209,952 - $334,210
17,139 Added 6.25%
291,453 $5.42 Million
Q3 2022

Nov 03, 2022
BUY
$7.06 - $15.52 $1.9 Million - $4.18 Million
269,506 Added 5605.37%
274,314 $3.52 Million
Q2 2022

Aug 12, 2022
SELL
$6.23 - $8.57 $71,065 - $97,757
-11,407 Reduced 70.35%
4,808 $34,000
Q1 2022

May 16, 2022
SELL
$5.31 - $8.31 $539,734 - $844,669
-101,645 Reduced 86.24%
16,215 $135,000
Q4 2021

Feb 14, 2022
BUY
$5.21 - $7.45 $287,789 - $411,523
55,238 Added 88.21%
117,860 $797,000
Q3 2021

Nov 09, 2021
SELL
$4.85 - $6.04 $418,147 - $520,744
-86,216 Reduced 57.93%
62,622 $333,000
Q2 2021

Aug 13, 2021
SELL
$4.29 - $6.05 $294,735 - $415,653
-68,703 Reduced 31.58%
148,838 $857,000
Q1 2021

May 13, 2021
SELL
$3.45 - $4.69 $127,467 - $173,281
-36,947 Reduced 14.52%
217,541 $1 Million
Q4 2020

Feb 11, 2021
SELL
$2.97 - $3.83 $36,860 - $47,534
-12,411 Reduced 4.65%
254,488 $849,000
Q3 2020

Nov 12, 2020
SELL
$2.97 - $5.08 $34,024 - $58,196
-11,456 Reduced 4.12%
266,899 $791,000
Q2 2020

Aug 12, 2020
BUY
$3.48 - $5.05 $82,378 - $119,543
23,672 Added 9.29%
278,355 $1.29 Million
Q1 2020

May 13, 2020
BUY
$2.61 - $5.21 $369,636 - $737,855
141,623 Added 125.26%
254,683 $981,000
Q4 2019

Feb 10, 2020
BUY
$3.67 - $5.7 $233,448 - $362,577
63,610 Added 128.63%
113,060 $424,000
Q3 2019

Nov 14, 2019
SELL
$3.89 - $7.43 $49,570 - $94,680
-12,743 Reduced 20.49%
49,450 $263,000
Q2 2019

Aug 14, 2019
BUY
$2.7 - $6.11 $94,316 - $213,434
34,932 Added 128.14%
62,193 $239,000
Q1 2019

May 15, 2019
BUY
$2.11 - $5.33 $55,127 - $139,256
26,127 Added 2303.97%
27,261 $139,000
Q4 2018

Feb 14, 2019
SELL
$1.92 - $3.62 $67,248 - $126,790
-35,025 Reduced 96.86%
1,134 $2,000
Q3 2018

Nov 14, 2018
BUY
$2.81 - $3.78 $81,751 - $109,971
29,093 Added 411.73%
36,159 $137,000
Q2 2018

Aug 14, 2018
SELL
$2.26 - $3.84 $56,420 - $95,865
-24,965 Reduced 77.94%
7,066 $22,000
Q1 2018

May 15, 2018
BUY
$2.39 - $4.01 $44,363 - $74,433
18,562 Added 137.81%
32,031 $76,000
Q4 2017

Feb 14, 2018
SELL
$2.51 - $4.4 $81,853 - $143,488
-32,611 Reduced 70.77%
13,469 $52,000
Q3 2017

Nov 14, 2017
BUY
$2.4 - $2.94 $110,592 - $135,475
46,080
46,080 $116,000

Others Institutions Holding CPRX

# of Institutions
326
Shares Held
94M
Call Options Held
19.1K
Put Options Held
51.1K
View Full List

About CATALYST PHARMACEUTICALS, INC.

CPRX Quotes by TradingView
  • Ticker CPRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 102,820,000
  • Market Cap $2.19B
  • Description
  • Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...
More about CPRX
Track This Portfolio

Track Barclays PLC Portfolio

Follow Barclays PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email